Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of LM-302 in CLDN18.2-positive advanced solid tumors
CTR20212820Phase 2Completed
- Sponsor
- LaNova Medicines
- Start
- Dec 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tpx-4589 in Nonhematologic neoplasms, sponsored by LaNova Medicines. Started Dec 2021; status: completed.
02
Drugs
tpx-4589
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20212820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212820.